Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E (2018) A phase 3 trial of L-glutamine in sickle cell disease
In addition, eloralintide, a selective, long-acting amylin receptor agonist: how the body handles the compound and clinical development
Due to limited human trials, side effects are not fully known
Transcription factor activity changes: GHK-Cu modulates activity of key transcription factors including NF-B (inflammation master regulator), AP-1 (stress response), Nrf2 (antioxidant response element activator), p53 (cell cycle and apoptosis regulator)
[PubMed: 16503554] 185
Graph 2 a represents the adrenal total protein, 2-b represents the adrenal MDA, 2-c represents the adrenal reduced glutathione, 2-d represents the adrenal catalase, 2-e represents the adrenal nitric oxide in induced hyperthyroid rats as well as those treated with folic acid and / or vitamin C